Creating new HIV vaccines using advanced delivery systems
Official title: Design and Engineering of VesiVax HIV Immunogen Formulations
Funded at Molecular Express, INC. · NIH-11172342 · Data updated 2026-11-12
This study is working on new HIV vaccines that use tiny particles to help your immune system recognize and fight the virus better, so you could get a stronger and more effective vaccine in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Express, INC. NIH-funded |
| Lab location | 1 site (Rancho Dominguez, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,999,866 |
| NIH project number | 75N93024C00018-0-9999-1 |
| Project ID | NIH-11172342 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of HIV infection who are seeking preventive measures.
✕Less likely to help
Patients who are already living with HIV or those who are not at risk for HIV infection may not benefit from this research.
What this research studies
This research focuses on developing innovative HIV vaccines that utilize particle-based delivery systems to enhance immune responses. By engineering specific HIV proteins and optimizing how they are presented to the immune system, the study aims to improve the effectiveness of vaccines in generating strong antibody responses. The approach involves using lipid- and polymer-based nanoparticles to deliver these immunogens, which may lead to better protection against HIV. Patients may benefit from a more effective vaccine that could provide broader immunity against the virus.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective HIV vaccine that provides better protection against the virus.
How similar studies have gone: Previous research has shown promise in using nanoparticle-based delivery systems for vaccines, indicating potential success for this novel approach.
Where this research is happening
-
Molecular Express, INC.
Rancho Dominguez, United States Active
Researchers
- Principal investigator: Ho, Samon — Molecular Express, INC.
- Study coordinator: Ho, Samon
Related research
Other NIH-funded projects on the same topics.
-
Developing a new vaccine adjuvant to enhance immune response against gonorrhea and aspergillosis
This study is working on a new helper ingredient for vaccines called ME-M-006, which aims to make vaccines more effective against infections like gonorrhea and a type of fungus, so that people can have better protection when they get vaccinated.
-
Developing a synthetic lung surfactant for preterm infants
This study is testing a new treatment called ME-1001, a synthetic lung surfactant, to help preterm babies with respiratory distress syndrome breathe better and stay healthier.
-
Creating a new formulation to improve flu vaccines
This study is testing a new type of flu vaccine that uses special ingredients to boost your immune response, aiming to provide better protection against the flu, especially during flu season.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.